
March 1 (Reuters) - Upstream Bio Inc UPB.O:
UPSTREAM BIO PRESENTS ADDITIONAL ANALYSES FROM THE PHASE 2 VIBRANT TRIAL OF VEREKITUG IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AT 2026 AAAAI ANNUAL MEETING
UPSTREAM BIO INC - PRIMARY ENDPOINT SHOWED REDUCTION OF -1.95 IN NASAL POLYP SCORE
UPSTREAM BIO INC - SECONDARY ENDPOINTS SHOWED REDUCTION IN NASAL CONGESTION SCORE BY -0.96